Navigation Links
Data for SemBioSys' insulin to be presented at the American Diabetes Association's 69th Scientific Sessions
Date:6/5/2009

CALGARY, June 5 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today announced that it will present the recent results of the Phase I/II study with its biosimilar human insulin in a late-breaking scientific poster at the American Diabetes Association's (ADA) 69th Scientific Sessions in New Orleans. The poster presentation will take place at the Morial Convention Center Poster Hall E on Sunday, June 7th and is entitled: "Analytical Characterization, Safety and Clinical Bioequivalence of Recombinant Human Insulin from Transgenic Plants," by Joseph Boothe and colleagues. The abstract for the presentation is available via the ADA website at http://ww2.aievolution.com/ada0901/index.cfm?do=abs.viewAbs&abs=7845.

The poster presentation details the clinical trial results of SemBioSys' first "in-man" clinical study of SBS-1000, a recombinant human insulin manufactured using the Company's proprietary platform, which allows for highly scalable, low cost production. The trial demonstrated that SBS-1000 was bioequivalent to Eli Lilly's Humulin(R) R, a widely-used human insulin in North America, with the expected safety profile. Additionally, SBS-1000 in humans showed pharmacokinetics and pharmacodynamics indistinguishable from Humulin(R) R and was well tolerated at pharmacologically active dosages. SemBioSys plans to publish the complete clinical trial results in a scientific journal in the near future.

About SemBioSys

Calgary, Alberta-based SemBioSys is a world leader in manufacturing high-value proteins and oils in plant seeds. With its unique, proprietary platform, SemBioSys provides partners with product enablement, exceptionally low cost and unprecedented scalability. The Company applies this platform with high selectivity to opportunities where it has a unique competitive advantage. Since its inception, SemBioSys has produced more than 50 non-native proteins and oils using its patented seed technology, demonstrating applicability across a broad range of industries such as pharmaceuticals, personal care and industrial products. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AIMilano, a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions and market size, the acceptance of an IND by the FDA in respect of clinical studies, the submission of a CTA to the appropriate European authorities, the successful initiation and timely and successful completion of clinical studies, the fact that Apo AIMilano is currently a development stage drug, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... 18, 2017 , ... Optofluidics today announced that it's changing ... company changed focus to making analytical tools for biopharmaceutical quality control. “We are ... CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson have steered ...
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy Lillis Foundation, ... education and advocacy. Founded in 2010 in memory of a single-parent mom and ... has become the most-consulted source for patient-focused information on C. diff infections in ...
(Date:4/19/2017)... , April 19, 2017  As a ... and Heroin Summit ,  Proove® Biosciences, Inc. ... genetics, environmental, and lifestyle factors to accurately predict ... University of Southern California (USC), the Interventional Pain ... Proove publish results showing that Proove Opioid Risk® ...
(Date:4/19/2017)... 19, 2017   Thermo Fisher Scientific Inc ... Procalcitonin MOnitoring SEpsis (MOSES) Study have been published ... Critical Care Medicine . Researchers from the study, ... Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis ... PCT (procalcitonin) assay to assess risk for 28 ...
Breaking Biology Technology:
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
Breaking Biology News(10 mins):